BioSpace News Archive

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the UBS Global Healthcare Conference on Monday, May 18, 2020 at 10:00 a.m. ET. The conference will be held in a virtual meeting format. Webcast information for this event will be accessible on the Eve

Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Diagnostic International Distribution S.p.A. of Milan (D.I.D.) as distributor of its Quality Assessment Products (QAPs™) for Italy. Under an agreement between the parties, D.I.D. has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Italy. As distributor, D.I.D. will provide

Toronto Innovation Acceleration Partners, Evotec SE and AmorChem II Fund L.P. are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.

VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-market under Nasdaq rules. VBL has also issued to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 6,349,208 of VBL’s ordinary shares. The

Enrollment of the pivotal SERENITY trials is progressing well, with topline data expected in mid-2020 The Company is assessing data for dose escalation in the TRANQUILITY study and is on track to report results in mid-2020 Recommended Phase 2 dose of BXCL701 identified for combination study with KEYTRUDA ® , leading to the initiation of the Phase 2 efficacy trial for advanced prostate cancer Strengthened balance sheet through follow-on offering raising approximately $60 million in net

Orig3n, Inc., a Boston-based company pioneering the future of wellness and health through genetics and biotechnology, has announced a comprehensive solution to enable COVID-19 testing for Massachusetts nursing home residents.

Elevated blood levels of toxic chemicals found in pesticides, nonstick cookware, and fire retardants have been tied to an increased risk for celiac disease in young people, new research shows.

Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020 Strong balance sheet with over $75M in cash Projected annual loss for 2020 narrows to $36-40M BURLINGTON, Mass.--( BUSINESS WIRE )-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs,

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET. A live webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com . A replay of the webcast will be available on Concert’s website for two weeks following the presen

Enhanced dystrophin expression in multiple muscle tissues and sustained functional benefit in DMD disease model following single low dose